A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
- Conditions
- Non Hodgkin LymphomaHodgkin Lymphoma
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Angiocrine Bioscience
- Target Recruit Count
- 130
- Registration Number
- NCT05181540
- Locations
- ๐บ๐ธ
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธUniversity Of Maryland School Of Medicine, Baltimore, Maryland, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
- Conditions
- Hodgkin LymphomaNon-hodgkin Lymphoma
- Interventions
- Biological: AB-205
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Angiocrine Bioscience
- Target Recruit Count
- 42
- Registration Number
- NCT03925935
- Locations
- ๐บ๐ธ
Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธThe University of California San Francisco, San Francisco, California, United States
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
- Conditions
- Myelodysplastic SyndromesAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia in RemissionOther Acute Leukemias
- Interventions
- Biological: Unmanipulated Umbilical Cord Blood (UCB)Biological: AB-110
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Angiocrine Bioscience
- Target Recruit Count
- 10
- Registration Number
- NCT03483324
- Locations
- ๐บ๐ธ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States